www.molnlycke.com
Open in
urlscan Pro
2606:4700::6812:9774
Public Scan
Submitted URL: https://t.jolly-pears.com/b?y=49ii4eh26orj6dpk74rjaphnchij0ohg60o32or26pj62dp25gh748hq49k78t3g78niurbfdhn6oub3ddiisorfdkh0...
Effective URL: https://www.molnlycke.com/corporate/
Submission: On December 11 via manual from IN — Scanned from US
Effective URL: https://www.molnlycke.com/corporate/
Submission: On December 11 via manual from IN — Scanned from US
Form analysis 1 forms found in the DOM
<form class="search_field">
<div class="icon-wrapper"><i class="icon fas fa-magnifying-glass"></i></div>
<div class="input-wrapper"><input type="search" name="q" placeholder="What are you looking for?" class="input" id="search_field"></div>
<div class="button-wrapper"><button class="button" type="button" title="Clear" disabled=""><i class="icon fas fa-xmark"></i></button></div>
</form>Text Content
WELCOME TO MÖLNLYCKE HEALTH CARE
MÖLNLYCKE CORPORATE
Find jobs, latest news, our financial reports and more.
Mölnlycke corporate
PRODUCTS AND SOLUTIONS
Get knowledge, learn about our products, get support and more.
Select market
Australia Austria Belgium (dutch) Belgium (Français) Brazil Canada (English)
Canada (Français) Czech Republic China Denmark Estonia Finland France Germany
Hungary India Italy Japan Latvia Latin America Lithuania Gulf Malaysia
Netherlands New Zealand Norway Poland Portugal Singapore South Korea Spain
Sweden Switzerland (Deutsch) Switzerland (Français) Switzerland (Italian) United
Kingdom United States Go to United States
Skip to content
* About us
* Careers
* Investor relations
* Sustainability
* News
* Contact
*
*
* About us
Mölnlycke is a world-leading MedTech company, with a purpose to revolutionise
care for people and planet.
* * Our purpose
* Mölnlycke story
* Our expertise
* Our governance
* * Partnering with us
* Innovation
* Clinical learning
* Annual report
* Careers
By bringing experts together, we drive collaborations that lead to
breakthrough innovations – which in turn have the power to transform
patients’ lives.
* * Application process
* Life at Mölnlycke
* * How we help you thrive
* Diversity, equity and inclusion
* Investor relations
*
*
* Sustainability
Sustainability is a strategic priority at Mölnlycke and WeCare is our
Sustainability roadmap for 2030.
* * Revolutionising care for people
* Revolutionising care for planet
* Sustainable portfolios
* Policy framework
* Sustainability reporting and governance
* * Ethical business
* Ethics Hotline
* Sustainable supply chains
* Distributor portal
* Commitments and recognition
* News
Collaboration is key to our success. Explore what we’re saying, what we’re
sharing and what we’re thinking.
* * Mölnlycke news
* Global events
* * Media room
* Contact
We are here to help if you need us and we are always pleased to hear from you
– whether you want to buy our products, discuss an existing order, visit one
of our sites or make a complaint.
*
*
Suggestions
* Annual report
* Sustainability
* Careers
* Instructions for use
* Diversity, Equity & Inclusion
All results
REVOLUTIONISE CARE. FOR PEOPLE AND PLANET.
WE DRIVE CHANGE THAT IMPROVES THE HEALTH AND WELLBEING OF PATIENTS AND THOSE WHO
CARE FOR THEM, WHILE REDUCING THE ENVIRONMENTAL FOOTPRINT OF HEALTHCARE.
Watch our video to find out more.
A WORLD-LEADING MEDTECH COMPANY
Mölnlycke Health Care is a world-leading MedTech company that specialises in
sustainable solutions for wound care and surgical procedures. Mölnlycke products
and solutions are used daily by hospitals, healthcare providers and patients in
over 100 countries around the world.
OUR STRATEGY
Mölnlycke applies a customer-centric approach to ensure we provide relevant
solutions for the future and continue to make a difference for customers and
patients.
Read more
OUR EXPERTISE
Our expertise extends across wound care, operating room solutions, antiseptics
and gloves.
* WOUND CARE
Mölnlycke is a leading global provider of wound care products and
therapy-based solutions.
Wound Care
* OPERATING ROOM SOLUTIONS
We provide an ecosystem of solutions for improved ways of working and more
sustainable outcomes.
Operating Room Solutions
* GLOVES
Innovative and sustainable solutions to enable hands to perform at their best
when it matters most.
Gloves
* ANTISEPTICS
We apply our expertise to reduce the risk of infections at every stage of the
patient journey.
Antiseptics
A strategic priority
WE CARE ABOUT SUSTAINABILITY
Sustainability is a strategic priority at Mölnlycke and WeCare is our
Sustainability roadmap for 2030. It means creating shared value for all our
stakeholders. It is a driver for growth, innovation and productivity and an
essential part of our employee value proposition.
How we work with sustainability
CAREERS AT MÖLNLYCKE
Why we go to work and what a career at Mölnlycke can offer. Do you want a career
that matters?
Careers
* CLINICAL LEARNING
Healthcare education never ends – even for healthcare professionals. With the
Mölnlycke Clinical Learning Hub, you can access online clinical learning
covering key wound care, surgical and healthcare topics and continue learning
and advancing your knowledge.
Explore our Clinical Learning Hub
* MÖLNLYCKE IS OWNED BY INVESTOR AB
Investor AB is listed on NASDAQ QMX Stockholm.
More investor information
MÖLNLYCKE WORLDWIDE
Mölnlycke products and solutions are used daily by hospitals, healthcare
providers and patients in over 100 countries around the world. Visit your
country site to learn more.
Select market
Australia Austria Belgium (dutch) Belgium (Français) Brazil Canada (English)
Canada (Français) Czech Republic China Denmark Estonia Finland France Germany
Hungary India Italy Japan Latvia Latin America Lithuania Gulf Malaysia
Netherlands New Zealand Norway Poland Portugal Singapore South Korea Spain
Sweden Switzerland (Deutsch) Switzerland (Français) Switzerland (Italian) United
Kingdom United States Go to United States
LATEST NEWS
* November 26, 2024
MÖLNLYCKE HEALTH CARE WINS SWEDISH SUSTAINABILITY TECH AWARD
Gothenburg, Sweden. 26 November 2024. The award ceremony was held on 25
November at the Nobel Prize Museum in Stockholm, Sweden where Susanne
Larsson, CFO & EVP IT, Digital Enablement, GBS and Indirect Procurement and
Caterina Camerani, VP Sustainability at Mölnlycke, accepted the award on
behalf of the company. “Our ambition is to transform our business to become a
global leader in sustainable healthcare. This award is proof that we are on
the right track. We are dedicated to equipping our customers with innovative
and sustainable healthcare solutions – for our customers, our employees, our
communities and the planet,” says Caterina Camerani, VP Sustainability at
Mölnlycke. Mölnlycke ProcedurePak® trays enhance efficiency¹ and help
decarbonise healthcare by reducing waste and greenhouse gas (GHG) emissions².
ProcedurePak® offers a sterile tray with all necessary components, reducing
setup time in the Operating Room by up to 40%¹, and packaging waste by up to
90%² compared to procedures conducted with single-packed products. In one
tray package, hospitals can simplify procurement and help ensure patient
safety³. The streamlined workflow decreases manual tasks, alleviating stress
and freeing up more time for healthcare professionals to focus on patient
care. Digital tools like the Mölnlycke Portal and CO2 calculator together
with ProcedurePak® Value Report allow hospitals to quantify reductions in
waste and GHG emissions, aligning with both sustainability and operational
objectives. The judging panel commented: “In recognition of outstanding
contributions to sustainability and innovation, this year’s Swedish award
celebrates a project that has significantly enhanced operational efficiency
while reducing environmental impact. Their commitment to sustainability is
further demonstrated by reducing waste, CO2 emissions and preparation time
while ensuring patient safety.” For more information, please contact:
[Contact card] Sofia Lindqvist About the Cagemini Nordic Sustainability Tech
Award The Capgemini Nordic Sustainability Tech Award celebrates organisations
across the Nordic region creating innovative technology solutions for a
sustainable future. The urgency of the global climate crisis demands
ground-breaking technology and IT service innovations that scale across
industries. The Nordic Sustainability Tech Award celebrates the inspirational
tech pioneers pushing the boundaries of sustainable IT and their role in
limiting the environmental and social impact of climate change. References 1
Greiling. A multinational case study to evaluate and quantify time-saving by
using custom procedure trays for operation room efficiency. (poster from
2010). 2 Assessing the carbon and waste benefits of moving to Procedure Packs
at Royal Liverpool and Broadgreen University Hospitals, NHS Trust, 2011. 3
Optimisation of perioperative procedural factors to reduce the risk of
surgical site infection in patients undergoing surgery: a systematic review
Key findings P. Calò , F. Catena, D. Corsaro, L. Costantini, F. Falez, B.
Moretti, V. Parrinello, E. Romanini, A. Spinarelli, G. Vaccaro, F. Venneri.
Discov Health Systems 2, 6 (2023).
https://doi.org/10.1007/s44250-023-00019-9.
* November 25, 2024
MÖLNLYCKE HEALTH CARE APPOINTS GUILLAUME JOUCLA AS CHIEF FINANCIAL OFFICER
Gothenburg, Sweden. 25 November 2024. Guillaume Joucla has been appointed new
Chief Financial Officer (CFO) at Mölnlycke Health Care. Guillaume Joucla will
take office as CFO and member of Mölnlycke’s Executive Leadership Team, as of
1 January 2025. Guillaume Joucla most recently comes from the role of VP
Global Finance & Strategic Projects Operating Room Solutions at Mölnlycke. He
has also led global cross-functional transformational programmes and held
General Manager positions of local operations. Guillaume Joucla wealth of
experience from his extensive career within Mölnlycke has equipped him with
deep insights into the company’s operations and strategic direction. “We are
thrilled to welcome Guillaume to our executive team,” said Zlatko Rihter, CEO
of Mölnlycke. “His leadership and expertise will be instrumental in driving
our financial strategy and supporting our growth initiatives going forward.”
Guillaume Joucla has a distinguished career; before joining Mölnlycke in 2008
he held senior management roles at ProxiMed Services and BioSteril. He holds
a Postgraduate degree in Finance & Management from IAE Aix-Marseille Graduate
School of Management, and a Master's degree in applied mathematics from
Aix-Marseille University. “I am excited to continue my journey at Mölnlycke
Health Care and contribute to our ongoing success,” said Guillaume Joucla. “I
look forward to working with the talented team to build on Mölnlycke’s strong
foundation and contribute to our future as we revolutionise care for people
and planet.” Guillaume will assume the new position as of 1 January 2025
and will be taking over from Susanne Larsson, who is leaving Mölnlycke to
pursue an opportunity outside of the organisation. -Ends- For more
information, please contact: [Contact card] Sofia Lindqvist
* November 18, 2024
MÖLNLYCKE HEALTH CARE AND OPERATION SMILE HELP TO CHANGE PEOPLE'S LIVES WITH
NEWLY INAUGURATED CLEFT CARE CENTRE IN PHILIPPINES
Gothenburg, Sweden. 19 November 2024. The Cebu Comprehensive Cleft Care
Center of Excellence is now officially inaugurated. This milestone is a
result of the longstanding partnership between Mölnlycke and Operation Smile
– a global non-profit charity organisation. The centre will bring
comprehensive care to people born with a cleft lip or palette (CLP) in the
region and is expected to serve 10,000 patients in the first three years of
its operations. The incidence of babies born with cleft lip and cleft palate
is higher in South-East Asia than in other regions globally. The new clinic
will offer life-changing surgeries and comprehensive cleft care to patients
in the region where access to healthcare services is difficult. “The support
from Mölnlycke in establishing the centre is grounded in our commitment to
ensure equitable access to healthcare for all and the vision we have for
achieving sustainable healthcare. A part of this vision is making the centre
self-sufficient, and that includes raising the level of knowledge of the
local healthcare professionals in the areas where Mölnlycke can offer
expertise”, comments Eric de Kesel, COO & EVP Sustainability, Mölnlycke.
“Cleft patients continue to be stigmatised and we are delighted to be able to
contribute to changing their lives and fully including them in society,” he
adds. “This clinic is a milestone for us, but also for cleft care globally,
as it is also a training hub. In a rather lengthy construction project, our
partner Mölnlycke has supported us financially while, in parallel with the
construction, we have jointly created and rolled out a training programme
with innovative methods and solutions,” says Emiliano Romano, Executive
Director, Operation Smile Philippines. “Together with some of our volunteers,
clinical specialists from Mölnlycke are training the local healthcare
professionals in areas such as infection prevention.” The Cebu Comprehensive
Cleft Care Center of Excellence is located at the Cebu City Medical Center
(CCMC) hospital, in the Philippines. It is a 2,000 m2 state-of-the-art
facility providing an optimal environment for delivering comprehensive CLP
services, including speech therapy, dental and psychosocial care - in
addition to the areas supporting the surgical flow, in alignment with the
vision of surgical care that Mölnlycke and Operation Smile share. It is also
fully manned by the local healthcare workers. -Ends- For more information,
please contact: [Contact card] Sofia Lindqvist About Operation Smile
Operation Smile is a leading global nonprofit bridging the gap in access to
essential surgeries and health care, starting with cleft surgery and
comprehensive care. We provide medical expertise, training, mentorship,
research and care through our dedicated staff and volunteers around the
world, working alongside local governments, nonprofits, and health systems,
and supported by our generous donors and corporate partners. Visit Operation
Smile for more information.
* October 24, 2024
MÖLNLYCKE® HEALTH CARE AND TRANSDIAGEN ANNOUNCE RESEARCH COLLABORATION TO
DRIVE INNOVATION IN WOUND CARE
Today, Mölnlycke Health Care, a world leading MedTech company, specialising
in wound care and wound management announce a research collaboration with
Transdiagen (TDG), a precision medicine company developing drugs and
diagnostics for chronic wound healing and tissue regeneration. The
collaboration aims to use TDG’s novel wound gene signatures to further
explore Mölnlycke products. Emma Wright, EVP Chief Medical Officer, Mölnlycke
commented, “We are excited by our research collaboration with TDG allowing us
to be at the forefront of advanced understanding of chronic wounds. This
opens up a wealth of opportunities for future innovation in the under
resourced and under prioritised area of wound care.” James Harding, CEO,
Transdiagen added “We are thrilled to be working with Mölnlycke on this R&D
programme. This collaboration will allow Mölnlycke access to TDG’s novel
models to generate functional insights regarding the mode of action of
innovative and biological wound treatment solutions. We believe this marks a
new chapter in the approach to data driven, evidence-based product
development for the treatment of complex wounds.” The collaboration will be
initiated shortly. For more information, please contact: Jennifer Doak
contact card About Mölnlycke Mölnlycke Health Care is a world-leading MedTech
company that specialises in innovative solutions for wound care and surgical
procedures. Mölnlycke products and solutions are used daily by hospitals,
health care providers and patients in over 100 countries around the world.
Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in
Sweden. www.molnlycke.com About Transdiagen Transdiagen (TDG) is a precision
medicine company developing drugs and diagnostics for chronic wound healing
and tissue regeneration. TDG is driven by the molecular understanding and
clinical outcome of chronic wounds and to delivering the right treatment, to
the right patient, at the right time. TDG has developed novel Ex Vivo models
built on clinically validated mRNA biomarkers linking clinical data and
patient outcomes. This is the most advanced disease understanding platform
for chronic wounds, and powers the creation of novel diagnostics and drugs.
The TDG development models and molecular insights translate laboratory data
to clinical outcomes, transforming the development lifecycle of novel
interventions directing efficacy, product development, disease, and patient
selection. TDG is headquartered in the UK. www.transdiagen.com
* October 1, 2024
MÖLNLYCKE® HEALTH CARE ACQUIRES P.G.F. INDUSTRY SOLUTIONS GMBH, THE
MANUFACTURER OF GRANUDACYN®, A RANGE OF SOLUTIONS FOR WOUND CLEANSING AND
MOISTURISING
Granudacyn® is a range of solution and gel products intended for use in the
cleansing, irrigation and moistening of various wound types. The high quality
and composition of Granudacyn ensures biocompatibility, allowing it to be
effectively used on a broad range of tissues in acute and chronic wounds, as
well as burns. Mölnlycke and P.G.F. have partnered together for more than
five years on the manufacturing and distribution of Granudacyn, with
Mölnlycke currently distributing Granudacyn in over 50 countries worldwide.
“The acquisition of P.G.F. will allow Mölnlycke to expand our Granudacyn
business and further develop our growing wound care portfolio. Granudacyn
effectively cleanses wounds, which supports healing, ultimately helping to
ease the burden of wounds” says Zlatko Rihter, CEO of Mölnlycke Health Care.
“I’m excited for our P.G.F. employees to become part of the Mölnlycke team
and to expand the reach of Granudacyn to patients most in need. In partnering
with P.G.F., Mölnlycke has demonstrated its commitment to helping patients
heal their wounds, improving their quality of life” says Peter Fritz, P.G.F.
founder. For more information, please contact: Jennifer Doak contact card
About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that
specialises in innovative solutions for wound care and surgical procedures.
Mölnlycke products and solutions are used daily by hospitals, health care
providers and patients in over 100 countries around the world. Founded in
1849, Mölnlycke is owned by Investor AB and headquartered in Sweden.
www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions
was founded in 2005 by Peter Fritz to develop and produce ecologically
compatible hypochlorous acid based products to protect the user and their
environment. The company is founded on more than 30 years of experience in
research, development, production, and worldwide distribution of medical and
measurement products. P.G.F. employs approximately 25 employees and is
headquartered in Elixhausen, Austria. For more information visit
www.veriforte.com
* September 23, 2024
MÖLNLYCKE AND ONDINE JOIN FORCES AGAINST HAIS
Mölnlycke Health Care partners with Ondine for Steriwave distribution
collaboration in the key markets of the UK, Europe and the Middle East.
Gothenburg, Sweden 23 September 2024. Mölnlycke® Health Care, a world-leading
MedTech company that specialises in innovative solutions for wound care and
surgical procedures and Ondine Biomedical Inc. (LON: OBI), a Canadian life
sciences company pioneering light-activated antimicrobial treatments, are
pleased to announce a strategic partnership to bring Ondine’s Steriwave®
nasal decolonisation technology to the United Kingdom, EU and Middle East
markets. This collaboration marks a significant milestone in the fight
against healthcare-associated infections (HAIs) and the growing threat of
antimicrobial resistance (AMR), as Steriwave safely reduces hospital
infections without generating AMR. Steriwave, a non-antibiotic,
light-activated nasal decolonisation therapy, has been clinically
proven[1[2][3][4][5] to reduce harmful pathogens in the nasal passages, a
common source of HAIs and cause of higher rates of mortality, length of stay
and readmissions. Mölnlycke’s established distribution networks, strong brand
and market presence in over 100 countries make it an ideal partner to
accelerate the adoption of Steriwave. The first market focus, starting later
this year, is the pivotal UK market where Steriwave is already deployed in a
number of National Health Service (NHS) Trusts, including, Mid Yorkshire
Teaching NHS Trust and Leeds Teaching Hospital NHS Trust. Steriwave is also
listed with NHS Supply Chain, a national body that manages the sourcing,
delivery and supply of healthcare products to the NHS and healthcare
organisations in England and Wales. The UK, with a total addressable market
of over 3 million major surgeries annually[6] and over 200,000 annual
intensive care unit (ICU) admissions,[7] has significant global influence in
setting best practice for patient care. Mölnlycke will incorporate Steriwave
as a key product in its infection control portfolio, enhancing its product
offerings with a focus on preventing HAIs and reducing AMR. Distribution will
commence in the UK in Q4 2024, followed by expansion into the EU and Middle
East regions in 2025, leveraging Mölnlycke’s extensive market presence to
ultimately broaden the impact of this innovative technology on a global
scale. Mölnlycke will spearhead sales and marketing efforts across the UK,
EU, and Middle East. Lina Karlsson, Executive Vice President Antiseptics,
Mölnlycke, stated: “Mölnlycke’s purpose is to revolutionise care for people
and planet. In the Antiseptics business area, we do this by making patient
skin decolonisation manageable and motivational. We believe that Steriwave
can improve the lives of millions of people, fitting perfectly with our
purpose and mission. The ability to rapidly eliminate multiple drug-resistant
pathogens without generating antimicrobial resistance is key to our
sustainability initiative, and complements our Hibiwash® brand skin prep
line, enabling us to provide comprehensive ‘nose-to-toes’ decolonisation
prior to surgery. Universal decolonisation is now a well-accepted practice to
improve surgical outcomes and produce significant cost savings to healthcare
systems.” Carolyn Cross, CEO of Ondine Biomedical, commented: “We are excited
to be partnering with Mölnlycke Health Care, whose global reach, corporate
vision and commitment to sustainable healthcare aligns perfectly with our own
core values, purpose and mission. The Mölnlycke collaboration represents a
transformative step towards our ambitious plans to combat HAIs and
antimicrobial resistance globally. We look forward to working with Mölnlycke
in these initial key markets and beyond.” HAIs remain a critical challenge
across the world, consuming approximately 6% of European public sector
budgets[8] and resulting in significant costs, avoidable deaths, and human
suffering. Post-surgical infections, in particular, extend recovery times and
often require prolonged antibiotic treatment, something the UK government is
actively seeking to reduce as part of its 5-year action plan for
antimicrobial resistance, published in May 2024[9]. Nasal decolonisation is
recommended in the 2016 WHO Global guidelines for the prevention of surgical
site infections[10], and the Society for Healthcare Epidemiology of America
(SHEA) guidelines, published in May 2023, recommend nasal decolonisation for
major surgical procedures[11]. Steriwave uses a patented light-activated
agent to rapidly eliminate infection-causing pathogens in a single, 5-minute
treatment. The process works so rapidly that pathogens do not have the
opportunity to develop resistance,[12] making it an effective alternative to
antibiotics. Hospitals using Steriwave have reported high levels of staff and
patient compliance. Steriwave has also been proven to be highly effective
against drug-resistant pathogens. A 2023 study showed that Steriwave is
highly effective (>99.99% kills in 20 seconds) against both moderately
drug-resistant (MDR) and extensively drug-resistant (XDR) pathogens.[13]
-Ends- About Ondine Biomedical Inc. Ondine Biomedical Inc. is a Canadian life
sciences company and leader innovating light-activated antimicrobial
therapies (also known as 'photodisinfection'). In addition to Steriwave,
Ondine has a pipeline of products, based on its proprietary photodisinfection
technology, in various stages of development. Ondine's nasal
photodisinfection system has a CE mark in Europe and the UK and is approved
in Canada and several other countries under the name Steriwave®. In the US,
it has been granted Qualified Infectious Disease Product designation and Fast
Track status by the FDA and is currently undergoing clinical trials for
regulatory approval. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications. About
Steriwave® Ondine’s Steriwave nasal photodisinfection system is a patented
technology using a proprietary light-activated antimicrobial
(photosensitiser) to destroy bacteria, viruses, and fungi colonising the
nose. The photodisinfection treatment is carried out by a trained healthcare
professional and is an easy-to-use, painless, two-step process. The
photosensitiser is applied to each nostril using a nasal swab, followed by
illumination of the area with a specific wavelength of red laser light for
less than five minutes. The light activates the photosensitiser, causing an
oxidative burst that is lethal to all types of pathogens without causing
long-term adverse effects on the nasal microbiome. A key benefit of this
approach — unlike antibiotics, which have resistance rates reported as high
as 81% — is that pathogens do not develop resistance to the therapy[i]. For
more information: Contact card Mathilda Blomsterberg References [1] Bryce E,
Wong T, Forrester L, et al. Nasal photodisinfection and chlorhexidine wipes
decrease surgical site infections: a historical control study and propensity
analysis [published correction appears in J Hosp Infect. 2015 Sep;91(1):93].
J Hosp Infect. 2014;88(2):89-95. (link) [2] Moskven E, Banaszek D, Sayre EC,
et al. Effectiveness of prophylactic intranasal photodynamic disinfection
therapy and chlorhexidine gluconate body wipes for surgical site infection
prophylaxis in adult spine surgery. Can J Surg. 2023;66(6):E550-E560. (link)
[3] Ondine Biomedical’s nasal photodisinfection cuts surgical site infections
by 66%. Press release 18 April 2023 (link) [4] Pre-op Nasal Decolonization
via Photodisinfection: A Pilot Study in Spinal Surgery Procedures at the
Ottawa Hospital. Poster presentation at IPAC Canada 2023 National Conference.
(link) [5] Street C, Pedigo L, Gibbs A, et al. Antimicrobial photodynamic
therapy for the decolonization of methicillin-resistant Staphylococcus aureus
from the anterior nares. In: Kessel DH, editor. Photodynamic therapy: back to
the future. 12th World Congress of the International Photodynamic
Association. Vol. 7380 of Proceedings series. Bellingham (WA): SPIE; 2009.
(link) [6] Surgical Procedure Volumes in UK from 2021-2029. Life Science
Intelligence; 2023 Jan. Volume 23. [7] Hospital Admitted Patient Care
Activity, 2011-22. Secondary Care Analytical Team, NHS Digital. Health and
Social Care Information Centre. 22 Sep 2022. (link) [8] OECD/European Union
(2020), Health at a Glance: Europe 2020: State of Health in the EU Cycle,
OECD Publishing, Paris. (link) [9] UK Government. UK 5-year action plan for
antimicrobial resistance 2024 to 2029. London: Department of Health and
Social Care; 2024. (link) [10] Surgical Site Infection Prevention: Key facts
on decolonization of nasal carriers of Staphylococcus aureus. World Health
Organization. (link) [11] Calderwood MS, Anderson DJ, Bratzler DW, et al.
Strategies to prevent surgical site infections in acute-care hospitals: 2022
Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. (link) [12] Pedigo
LA, Gibbs AJ, Scott RJ, et al. Absence of bacterial resistance following
repeat exposure to photodynamic therapy. Proc. SPIE 7380, Photodynamic
Therapy: Back to the Future, 73803H (2009). (link) [13] Romo-Bernal C, Sabino
C, Chavez M, et al. Antimicrobial Photodynamic Therapy Against Extensively
Drug-Resistant (XDR) Gram-Negative Isolates with Novel Antibiotic Resistance
Factors. Poster presented at: ICPIC2023; 12-15 September 2023; Geneva. (link)
* September 9, 2024
MÖLNLYCKE AWARDED A PLATINUM MEDAL FROM ECOVADIS IN 2024
Mölnlycke has been awarded the platinum medal in Ecovadis Sustainability
Rating, which places us in the top 1 percent of all companies assessed.
EcoVadis is a globally trusted provider of business sustainability ratings
with a network of more than 130,000 rated companies. Their rating recognises
Mölnlycke’s strengths in environmental impact management, labour & human
rights interactions, ethical governance and sustainable supply chain
partnerships. Mölnlycke have been utilising feedback from EcoVadis, business
partners and customers to drive continual improvement in sustainability each
year. The acknowledgement of Mölnlycke’s achievments in these areas motivates
us to be bolder and go further, driving positive change both for people and
planet.
* July 15, 2024
MÖLNLYCKE HEALTH CARE ANNOUNCES US $15M INVESTMENT IN NEXT-GENERATION
ENZYMATIC THERAPEUTICS COMPANY MEDIWOUND LTD.
Gothenburg, Sweden 15 July 2024. Mölnlycke Health Care, a world-leading
MedTech company specialising in solutions for wound care and surgical
procedures, announced today an investment of US $15m in MediWound Ltd.
(Nasdaq: MDWD)(MediWound) through a definitive share purchase agreement in a
private investment in public equity (PIPE). MediWound, a global leader in
next-generation enzymatic therapeutics focused on non-surgical wound
debridement, has a vision to improve the existing standards of care and
patient experiences, while reducing costs and unnecessary surgeries.
Debridement is a standard of care step to prepare the wound bed for healing
and can help in the management of infection. It involves the removal of dead
or devitalised tissue from a wound. “We are very excited to make this
strategic investment in MediWound. It aligns with our strategy to bring
radical innovations into the wound care space and provide alternative
solutions to the more traditional debridement options to improve clinical
outcomes and patient experience,” said Zlatko Rihter, CEO of Mölnlycke. “This
investment will support Mölnlycke’s Wound Care mission to ‘help free patients
from the burden of wounds’ and I look forward to this partnership.” Mölnlycke
and MediWound have also entered into a collaboration agreement to strengthen
their partnership. Under the key terms of this agreement, Mölnlycke is
granted specific rights, including having a representative attend meetings of
MediWound’s R&D Committee and will also be able to participate in potential
strategic partnership discussions and M&A processes under certain
circumstances. “We are delighted to have Mölnlycke’s support. This
substantial investment will empower us to strengthen our strategic plans,
creating significant long-term value for our stakeholders and help to improve
standards of care for patients” said Ofer Gonen, CEO of MediWound. For more
information, please contact: Jennifer Doak, Global Communications Director
Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 Ellie
Hanson, FINN Partners for MediWound Email: ellie.hanson@finnpartners.com
Phone : +1 929-588 2008 About Mölnlycke Mölnlycke Health Care is a
world-leading MedTech company that specialises in innovative solutions for
wound care and surgical procedures. Mölnlycke products and solutions are used
daily by hospitals, health care providers and patients in over 100 countries
around the world. Founded in 1849, Mölnlycke is owned by Investor AB and
headquartered in Sweden. www.molnlycke.com About MediWound MediWound Ltd.
(Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics
focused on non-surgical tissue repair. The Company specializes in the
development, production and commercialization of rapid and effective
biologics that improve existing standards of care and patient experiences,
while reducing costs and unnecessary surgeries. MediWound first drug,
NexoBrid®, is an FDA and EMA-approved orphan biologic for eschar removal in
deep partial-thickness and/or full-thickness thermal burns, which can
significantly reduce surgical interventions. Utilizing the same core
biotherapeutic enzymatic platform technology, MediWound has developed a
strong R&D pipeline, including the company’s lead drug under development,
EscharEx®. EscharEx is a Phase III-ready biologic for the debridement of
chronic wounds, offering significant potential advantages over the dominant
$360+ million product and an opportunity to expand the market. For more
information visit www.mediwound.com and follow the Company on LinkedIn.
* July 12, 2024
JULY, THE PEAK OF THE GRILL SEASON, AND GRILL-RELATED BURN INJURIES!
How to stay safe and avoid burns Make sure your grill is in a safe location.
The grill should be placed well away from the home, deck railings and out
from under eaves and overhanging branches. Only grill outside. Keep children
and pets away. Keep children and pets at least one meter away from the grill
area. Keep your grill clean. Keep your grill clean by removing grease or fat
buildup from the grills and in trays below the grill. Let it cool completely.
When you are finished grilling, let the coals cool completely before
disposing of them in a metal container.
* July 10, 2024
MÖLNLYCKE SETS SAIL WITH OCEAN BIOFUEL: A STEP TOWARDS GREENER LOGISTICS
Longstanding partners, Mölnlycke Health Care and Scan Global Logistics (SGL),
have entered an agreement for the purchase and deployment of ocean biofuel
covering trade lanes from Asia to Europe to further reduce carbon emissions.
This decision supports the global MedTech company Mölnlycke's commitment to
reducing greenhouse gas (GHG) emissions and reaching Net Zero by 2050. For
over 15 years, Scan Global Logistics have had a close global partnership with
Mölnlycke, marked by a shared focus on supply chain optimisation and
mitigating greenhouse gas (GHG) emissions associated with maritime
transportation. In recent years, this collaboration has seen a heightened
emphasis on sustainability initiatives, culminating in exploring actions to
reduce environmental impact, which resulted in the company now buying ocean
biofuel. Eric de Kesel, COO & EVP Sustainability, Mölnlycke, elaborates on
this decision: “We are committed to driving our sustainability efforts
forward and firmly believe we can reduce emissions while maintaining the
quality of our business operations. The partnership with Scan Global
Logistics to purchase a significant amount of biofuel for our ocean shipments
is important and beneficial from a business, economic, and environmental
standpoint, particularly for our Asia-Europe routes.” Striking a balance:
Sustainable and economical solutions in logistics Both companies recognise
the importance of offering tangible solutions to address climate
change-related concerns, anchoring their collaboration in a mutual
commitment to push for positive change. Kim Fischer, Corporate EVP, Global
Sales & Corporate Strategic Accounts in Scan Global Logistics, reinforces
this commitment: “Mölnlycke is very important to us, and our relationship
dates back over a decade. This initiative underlines the dynamic and
innovative approach that both companies are investing in a successful
business collaboration. Further sustainability initiatives have already been
discussed with Mölnlycke, and we value such entrepreneurship, which aligns
with our business approach.” Marc Bach Spangsberg Sørensen, Global Head of
Program Management at Scan Global Logistics, continues: ”We are dedicated to
expanding the portfolio of relevant products offered to our customers in an
ever-changing world. Through strategic collaborations, we promote the agenda
for alternative fuel types, contributing to the long-term transition to
low-emisssion transport solutions.” Central to this collaboration is the
ability to provide customers like Mölnlycke with accessible, measurable, and
ready-for-use products that facilitate GHG emission reduction. By leveraging
biofuel for ocean freight, SGL aim to deliver environmental and economic
benefits through cost-effective pricing structures. Partnerhips as drivers
for positive change Martin Andersen, Global Head of Sustainability & ESG at
Scan Global Logistics, is excited about the collective courage among
companies which will support the demand for ocean biofuel and actual emission
reductions: ”It is paramount and uplifting to see responsible companies drive
their decarbonisation journey. It is a challenge, but we all must contribute
and support each other with collaboration across industries and supply
chains, which is essential to making progress. The window for meaningful
change is closing; now is the time to drive collective courage for a
low-carbon future.” In conclusion, this partnership for ocean biofuel
represents a positive step towards low-carbon logistics. While navigating the
complexities of modern logistics, collaborations like these serve as examples
of optimism and pave the way towards a more sustainable future for the
industry.
* July 4, 2024
MÖLNLYCKE’S SCIENCE-BASED TARGETS VALIDATED
Today, Mölnlycke Health Care, a world leading MedTech company, announces that
its near-term GHG emission reduction targets submitted to the SBTi have been
validated and deemed to be compliant with all applicable requirements.
Specifically, Mölnlycke has committed to reduce absolute scope 1 and 2 GHG
emissions by 50% by 2030, from a 2021 base year, to increase active annual
sourcing of renewable electricity from 23% in 2021 to 100% by 2024, and to
continue sourcing of 100% renewable electricity through 2030. Furthermore,
the company committed to reducing absolute scope 3 GHG emissions from
purchased goods and services, fuel and energy related activities, upstream
transportation and distribution and waste generated in operations by 20% by
2028, from a 2021 base year. Finally, Mölnlycke committed that 63% of its
suppliers by emissions covering purchased goods and services, capital goods,
and upstream transportation and distribution, will have set science-based
targets by 2028. “SBTi validation is a key milestone in our long-term
strategy to help decarbonise the healthcare sector” said Zlatko Rihter, Chief
Executive Officer, Mölnlycke Health Care. “We are committed to reach Net Zero
by 2050 at the latest, and are accelerating the process of minimising both
the direct and indirect impact of our operations on the planet.” Mölnlycke
stands well poised for reaching the targets through a series of impact
initiatives: For scope 1 and scope 2 targets concerning our own manufacturing
facilities and headquarters, Mölnlycke’s implementation of a renewable
electricity roadmap is well underway and will be achieved through a
combination of virtual Power Purchase Agreements, renewable energy
certificates (RECs) and investments in higher additionality energy sources,
e.g. photovoltaic systems. For scope 3 and the supplier engagement target,
Mölnlycke has already initiated activities under the Sustainable Procurement
framework aimed at increasing collaboration with suppliers to bring
innovation in raw materials and improved transportation routes that are
needed to transition to a low-carbon economy. Mölnlycke are ensuring a
defined set of suppliers commit to reducing emissions through the SBTi. The
official information on Mölnlycke’s commitment can be found here. About SBTi
The Science Based Targets Initiative (SBTi) is a global partnership made up
of leading climate organisations, including the Carbon Disclosure Project,
the United Nations Global Compact, World Resources Institute (WRI) and the
World Wide Fund for Nature (WWF). The SBTi defines and promotes best practice
in emissions reductions and Net-zero targets in line with science. It
provides technical assistance and expert resources to companies that set
science-based targets, to ensure their alignment with the Paris Agreement, to
limit global warming to 1.5C.
* June 28, 2024
MÖLNLYCKE SUCCESSFULLY PRICES A EUR 500M BOND MATURING 2034
The bond was more than five times oversubscribed with an orderbook of over
EUR 2,700M at its peak. There was strong and widespread demand from leading
investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics
18%, France 12% and Other 10%. Asset Managers represented 87% of investors,
followed by Insurance and Pension Funds with 9% and Banks with 4%. The
proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding
EUR 500M notes maturing in 2025 as well as for general corporate purposes.
The bond further extends the duration of Mölnlycke’s well-spread debt
maturity profile. The bond will be listed on the Euro MTF market of the
Luxembourg Stock Exchange. BNP Paribas, ING, JP Morgan and SEB acted as joint
bookrunners for the transaction.
* May 31, 2024
EUR BOND ISSUE AND TENDER ANNOUNCEMENT
Mölnlycke intends to issue a new 10-year EUR bond under its Euro Medium Term
Note (EMTN) programme. The bond will be listed on the Euro MTF market of the
Luxembourg Stock Exchange. At the same time Mölnlycke invites its holders of
the outstanding EUR 500m bond due February 2025 note to tender any and all of
their notes for purchase by the company. Read the full announcement here.
* May 17, 2024
MÖLNLYCKE ANNOUNCES NEW PARTNERSHIP WITH BURN SURVIVORS ORGANISATION PHOENIX
SOCIETY
Since 1977, Phoenix Society has served burn survivors, their loved ones, burn
care professionals, researchers and others committed to empowering the burn
community to enable transformational healing. With the overarching vision of
uniting the voice of the burn community globally to “advance lifelong
healing, optimal recovery, and burn prevention”, the Phoenix Society offers
programmes, tools, education and events to bring this vision to life. With
our wide range of burn care solutions including for example cleansing, gentle
wound dressings and scar management, Mölnlycke is uniquely positioned to
support Phoenix Society initiatives. Our advanced wound care dressings are
enabled by Safetac® technology, a gentle silicone adhesive that reduces pain
and minimises skin trauma of burn survivors at dressing change. Mölnlycke
also provide information about burn dressings and healing through educational
content, clinical evidence, and tips and tricks on how to apply burn care.
Inline quote: Anders Andersson The power of partnership The partnership
between Phoenix Society and Mölnlycke brings together two organisations
driven by a mission to make survivors’ healing easier and their lives fuller
by reaching survivors earlier, minimising the impact of burns and giving
survivors the solutions, resources and community needed to facilitate
recovery and support.
* May 15, 2024
MÖLNLYCKE HEALTH CARE EXPANDS INVESTMENT IN TAMER MÖLNLYCKE CARE JOINT
VENTURE
The Tamer Mölnlycke Care joint venture was initiated in 2021 with the
agreement to develop a customised surgical procedure tray factory in Saudi
Arabia, with first production expected in Q4 2024. The increased investment
allows for an expansion in the range of Mölnlycke products manufactured and
distributed in the country and to the neighbouring region. Adding drapes and
gowns, emollient range and selected wound care products to the offering
allows more healthcare professionals and patients in the region to benefit
from Mölnlycke products and solutions. Zlatko Rihter, CEO, Mölnlycke Health
Care comments “To ensure we meet customer demand, geographical expansion is a
strategic priority for Mölnlycke Health Care. Increased investment in our
existing long-term partnership with Tamer Group will importantly enable
healthcare professionals and patients in Saudi Arabia access to our quality
products and solutions helping to improve outcomes, and is a step closer to
realising the potential of this rapidly growing healthcare market.” Speaking
on behalf of Tamer Group, Chairman Ayman Tamer adds “This investment is key
to enabling future growth in the region as outlined in the Saudi Vision 2030
- supporting the regional healthcare ecosystem, including exporting goods to
the Middle East and Africa region, whilst developing local skills and
expertise.” Mahmoud Wagih, CEO, Tamer Mölnlycke Care comments “I am delighted
to lead this business where Mölnlycke and Tamer will build a strong,
long-term successful joint venture, bringing superior health care solutions
to our region.” The Tamer Mölnlycke Care joint venture is a long-term
agreement between two organisations who have been working in partnership over
the past decade; and are committed to meeting customer demand in the evolving
healthcare landscape of Saudi Arabia and the wider region. For more
information, please contact: Liz Neal Director of Communications
Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke
Mölnlycke is a world-leading medical products and solutions company that
equips healthcare professionals to achieve the best patient, clinical and
economic outcomes. The core business is within the four Business Areas Wound
Care, Operating Room Solutions (ORS), Gloves and Antiseptics. Mölnlycke
employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and
the company operates in more than 100 countries worldwide. Mölnlycke is owned
by Patricia Industries AB, which is part of Investor AB, an engaged owner of
high-quality, global companies founded by the Wallenberg family in 1916.
www.molnlycke.com
* April 12, 2024
MÖLNLYCKE HEALTH CARE AGREES TO ACQUIRE LEADING WOUND CLEANSING MANUFACTURER
TO CONSOLIDATE ITS POSITION AS GLOBAL LEADER IN WOUND CARE
Gothenburg 12 April 2024: Mölnlycke, a world leading MedTech company
specialised in wound care and wound management, announced today it signed an
agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian
manufacturer of Granudacyn wound cleansing and moisturising solutions.
Mölnlycke and P.G.F. have worked together for five years on the manufacturing
and distribution of Granudacyn, a range of solution and gel products intended
for use in the cleansing, irrigation and moisturisation of various wound
types. The high quality and composition of Granudacyn ensures good
biocompatibility, allowing it to be effectively used on a broad range of
tissues in burns, as well as acute and chronic wounds. Mölnlycke currently
distributes Granudacyn in over 50 countries around the world. “With an ageing
population in combination with increased chronic wounds, such as diabetic
foot ulcers or venous leg ulcers, it is our obligation to help ease the
burden of wounds on national healthcare regimes” says Zlatko Rihter, CEO of
Mölnlycke Health Care. “The acquisition of P.G.F. and its state-of-the-art
manufacturing plant, will allow Mölnlycke to aggressively expand our
Granudacyn business to improve the lives of even more patients.” “I’m excited
for P.G.F. to become part of Mölnlycke and for the team to continue to
manufacture products that support Mölnlycke’s Wound Care mission to help free
patients from the burden of wounds” says Peter Fritz, P.G.F. founder and CEO,
who will continue to lead this team and manufacturing process from P.G.F.’s
Austria headquarters. Closure is expected after certain milestones are
reached and will be communicated separately. For more information, please
contact: Jennifer Doak Global Communications Director Wound Care Email:
jennifer.doak@molnlycke.com Phone: +1 678 206 6179 About Mölnlycke® Mölnlycke
Health Care is a world-leading MedTech company that specialises in innovative
solutions for wound care and surgical procedures. Mölnlycke products and
solutions are used daily by hospitals, health care providers and patients in
over 100 countries around the world. Founded in 1849, Mölnlycke is owned by
Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F.
Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter
Fritz to develop and produce ecologically compatible hypochlorous acid based
products to protect the user and their environment. The company is founded on
more than 30 years of experience in research, development, production, and
worldwide distribution of medical and measurement products. P.G.F. employs
approximately 25 employees and is headquartered in Elixhausen,
Austria. www.veriforte.com.
* March 28, 2024
MÖLNLYCKE INTEGRATED ANNUAL REPORT 2023
Performance highlights Mölnlycke reported strong growth in 2023, with net
sales reaching EUR 1,924 million, an 8% increase in constant currency rates.
The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic
growth and market share gains across most markets. Sustainability
achievements We made significant strides in operationalising our
sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission
reduction targets were validated by the Science Based Targets initiative.
Noteworthy progress was made in our journey towards 100% fossil-free
electricity by the end of 2024, with 61% fossil-free electricity share in
2023. We also achieved a 20% reduction in overall absolute greenhouse gas
emissions across the entire value chain compared to the 2021 baseline.
Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our
portfolio in terms of net sales. Zlatko annual report news quote Innovation
and quality highlights To enhance surgical performance, Mölnlycke introduced
hand scanning technology using artificial intelligence and machine learning
for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex®
Border Post-Op product family globally and registered Hibiwash®, - the new
colour- and fragrance-free Hibi formula. We also successfully completed the
transition to Medical Device Regulation (MDR), one of the first MedTech
companies to do so. Strategic investments Mölnlycke secured long-term
financing through a EUR 400 million Eurobond and a EUR 350 million Revolving
Credit Facility. We also decided to invest EUR 60 million to increase
production capacity, including a new Mepilex Border Flex production line and
a new Ethylene Oxide sterilisation unit in Finland.
* March 20, 2024
IN 2023 MÖLNLYCKE WAS AWARDED A GOLD MEDAL FOR SUSTAINABILITY BY ECOVADIS
The benchmarking procedure Mölnlycke are in the second year of working with
EcoVadis as an independent and credible organisation to benchmark strengths
and improvement opportunities. The rating process required extensive amounts
of data and documentation, and therefore teamwork between global
sustainability, legal and compliance, information technology, procurement
excellence, and people experience teams. Our submission was assessed over a
four week period. As a continuation from the previous assessment, results and
feedback will be used to prioritise improvement plans. The result A gold
medal is awarded to the all top 5%, and our score puts us into the top 3% of
all organisations from all industries worldwide. Particularly recognized
during the submission were Mölnlycke's commitment to Science Based Targets
and measurable improvements in emissions, the strength of Mölnlycke
procedures relating to human rights, demonstrable progress in gender
equality, and the availability of the Ethics Hotline to all Mölnlycke's
stakeholders The results certificate is available to download for
verification below, EcoVadis will also provide a detailed validated scorecard
to users of their platform.
* May 5, 2023
MÖLNLYCKE SIGNS A EUR 350 MILLION REVOLVING CREDIT FACILITY
The facility is backed by a group of seven leading global and regional banks,
well diversified to match Mölnlycke’s geographical footprint. The banks are
BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB as mandated lead
arrangers. SEB acted as the coordinator, documentation agent and facility
agent for the transaction. For more information, please contact: Liz Neal
Director of Communications Email: liz.neal@molnlycke.com Phone: +44
7787432560 About Mölnlycke Mölnlycke is a world-leading medical products
and solutions company that equips healthcare professionals to achieve the
best patient, clinical and economic outcomes. The core business is within the
four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and
Antiseptics. Mölnlycke employs around 8,700 people. The headquarters are in
Gothenburg, Sweden, and the company operates in more than 100 countries
worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of
Investor AB, an engaged owner of high-quality, global companies founded by
the Wallenberg family in 1916. www.molnlycke.com
* March 26, 2021
MÖLNLYCKE TO HELP ESTABLISH CLEFT CARE CENTRE IN THE PHILIPPINES
Being born with a cleft lip or palate is more than just a cosmetic problem.
Many children have issues eating or speaking. They can grow up isolated,
unable to socialise and deprived of opportunities. The Philippines has one of
the highest incidences of cleft palate and cleft lip in the world. A simple
surgical procedure can correct cleft problems. But access to healthcare is
low in the country, particularly for people living outside the two main
islands, and there is a need to enhance the specialist cleft care skills of
healthcare professionals. 10,000 surgeries in three years The centre, which
is planned to open in Q4 2021, will serve the 27 million people who live on
Cebu or one of the 150+ surrounding islands. In its first three years,
Operation Smile and Mölnlycke estimate that the centre will support up to
10,000 surgeries, via a hub and spokes model in the community. More than
26,000 patients will receive consultations and 1,800 community health workers
will be trained – alongside 400 Operation Smile volunteers and hospital
staff. Supporting with funds, products and expertise Mölnlycke has committed
to an initial three-year partnership agreement to support the centre at Cebu.
In addition to funds, the company will donate products, train healthcare
professionals in infection prevention and provide logistics support. As
expertise within Cebu and the surrounding area grows, the ambition is for the
centre to become less reliant on direct support and more self-sufficient.
Zlatko cleft centre Quote Follow #Cebu10000 #Cebu10000 is the first time
Mölnlycke has supported healthcare infrastructure and marks a significant
step-change in the company’s relationship with its global charity partner
Operation Smile. Since 2004, when Mölnlycke began its support of Operation
Smile, the company has donated funds, volunteer time and more than 1.5
million pairs of Biogel® surgical gloves to support cleft procedures. A model
of cleft care Bill Magee Cleft centre Quote Press contact Liz Neal Director
of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About
Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that
specialises in innovative solutions for wound care and surgical procedures.
Mölnlycke products and solutions are used daily by hospitals, health care
providers and patients in over 100 countries around the world. Founded in
1849, Mölnlycke is owned by Investor AB and headquartered in
Sweden. www.molnlycke.com
* Jun 04 - Jun 05, 2024
SUSTAINABLE HEALTHCARE FOR TOMORROW
Krakow, Poland
* Aug 18 - Aug 22, 2024
ISBI 2024
Birmingham, UK
* Sept 06 - Sept 08, 2024
DFSG 2024
Valencia, Spain
* Sept 18 - Sept 20, 2024
PISA INTERNATIONAL DIABETIC FOOT COURSE
Pisa, Italy
* Sept 18 - Sept 20, 2024
ERAS 2024
Malaga, Spain
* Sept 25 - Sept 27, 2024
EPUAP 2024
Lausanne, Switzerland
* Mar 26 - Mar 28, 2025
EWMA 2025
Barcelona, Spain
Mölnlycke Health Care is a world-leading MedTech company that specialises in
innovative solutions for wound care and surgical procedures.
Quick links
* About us
* Contact us
* Our locations
* Annual report
* Adverse event report
* Products - Instructions for Use
* Symbols glossary
* SSCP - Summary of Safety and Clinical Performance
* ISCC standard
* Waste handling
Go to market
* © 2024 Mölnlycke AB
* Privacy centre
* Terms of use
* Cookie policy
* Sitemap
*
*
*
*
*